Emergent BioSolutions Inc. (EBS): Free Cash Flow
$156.80M
Year ended 2025-12-31
$85.90M
Trailing 12 months to 2026-06-30
-16.9%
5-year compound annual growth
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $156.80M | +338.0% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $35.80M | n/m | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | -$257.90M | n/m | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | -$149.90M | n/m | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | $96.10M | -75.7% | 2024-03-08, From 2021-01-01 |
| 2020-12-31 | $395.00M | +290.7% | 2023-12-11, From 2020-01-01 |
| 2019-12-31 | $101.10M | n/m | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | -$30.30M | n/m | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $153.30M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | -$21.60M | n/m | 2019-02-22, From 2016-01-01 |
| 2015-12-31 | -$2.29M | n/m | 2018-02-23, From 2015-01-01 |
| 2014-12-31 | $81.64M | +48.6% | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | $54.95M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$14.20M | n/m | 2015-03-09, From 2012-01-01 |
| 2011-12-31 | -$41.84M | n/m | 2014-03-10, From 2011-01-01 |
| 2010-12-31 | $75.92M | n/m | 2013-03-08, From 2010-01-01 |
| 2009-12-31 | -$3.42M | n/a | 2012-03-09, From 2009-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $156.80M | +338.0% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $136.66M | -23.5% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $141.78M | -27.7% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $121.23M | -29.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $45.99M | -73.1% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $327.58M | +61.1% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $136.42M | +436.8% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$472.00M | n/m |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $156.89M | n/m |
Compare EBS, PCRX, CORT, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗